Toronto, Ontario -- September 27, 2012 -- Theralase Technologies Inc. (TSX-V: TLT) announced today that its Theralase therapeutic laser system has now been proven clinically effective in the relief of chronic knee pain and for the treatment of osteoarthritis.
Dr. Arkady Mandel , Chief Scientific Officer of Theralase
said, “A key finding from the Theralase clinical study was that a significant reduction
in the VAS pain score was obtained 30 days after discontinuing treatment
proving that for patients who suffer from severe chronic knee pain, the Theralase
technology is an effective solution. Because of the excellent safety and
efficacy profile of the technology proven during the clinical study, it can be
stated that Theralase’s non-invasive, superpulsed laser therapy represents a
promising therapeutic alternative to pharmaceuticals for patients suffering from
chronic knee pain and OA due to degenerative and inflammatory conditions. This
clinical study has now paved the way for widespread acceptance of this
technology by the medical community and thus provides a cost effective treatment
option for anyone involved in treating pain on a regular basis, including: medical
doctors, chiropractors and physical therapists”.
Chronic
pain is a complex process that profoundly affects a person’s life, forcing alterations
in professional, social and other aspects of everyday activities. Knee pain is
the third most common pain reported to healthcare practitioners behind low back
pain and headaches. Osteoarthritis of the knee is the most common type of
arthritis and the major cause of chronic musculoskeletal pain and mobility
disability in the elderly, which places a significant burden on the healthcare
system. OA affects approximately 10% of the population over 60 years of age and
an astounding 85% of the population over 75 years of age, leading to estimated
socioeconomic costs of over $185.5 billion per year in the US alone. The
prevalence of osteoarthritis is rapidly increasing; due to the aging population
and an increase in the prevalence of obesity, with an estimated 44% of the US
population to be classified as obese by the year 2030. Current treatments for
chronic knee pain and OA include pharmaceutical anti-inflammatories,
painkillers and corticosteroids, which offer only temporary pain relief at
best, with minimal mid to long-term benefits and unfortunately severe negative
side effects.
About Theralase
Technologies Inc.:
Theralase
Technologies Inc., founded in 1995, designs, develops, manufactures and markets
patented, superpulsed laser technology utilized in biostimulation and
biodestruction applications. Theralase technology is safe and effective in
treating pain, inflammation and for tissue regeneration of neural muscular
skeletal conditions and wound healing in both humans and animals. Theralase
complies with all FDA, Health Canada, CE and international regulatory approvals
to ensure effective, safe and high quality products. Theralase also develops
patented Photo Dynamic Compound (PDC) technology focused at targeting and
destroying cancers, bacteria and viruses when light activated by Theralase’s
proprietary and patented laser technologies.
For
further information please visit www.theralase.com,
regulatory filings may be viewed by visiting www.sedar.com.
This press release
contains forward-looking statements, which reflect the Company's current
expectations regarding future events. The forward-looking statements involve
risks and uncertainties. Actual results could differ materially from those
projected herein. The Company disclaims any obligation to update these
forward-looking statements.
Neither TSX Venture
Exchange nor its Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchanges) accepts responsibility for the adequacy
or accuracy of this release.
For More Information,
please contact:
Roger
Dumoulin - White,
President and
CEO
416-447-8455 begin_of_the_skype_highlighting 416-447-8455 ext. 225
